TScan Therapeutics (TCRX) Non Operating Interest Expenses (2022 - 2026)

TScan Therapeutics (TCRX) has reported Non Operating Interest Expenses for 5 consecutive years, with $699000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 1.45% year-over-year to $699000.0 in Q2 2026; TTM through Jun 2026 was $2.8 million, a 10.32% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 24.2% from the prior year.
• Non Operating Interest Expenses was $699000.0 for Q2 2026 at TScan Therapeutics, up from $689000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $982000.0 in Q3 2023 and troughed at $201000.0 in Q3 2022.
• A 5-year average of $796562.5 and a median of $818000.0 in 2023 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 388.56% in 2023 and slipped 29.2% in 2025, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $975000.0 in 2022, then slipped by 12.62% to $852000.0 in 2023, then fell by 7.98% to $784000.0 in 2024, then decreased by 10.46% to $702000.0 in 2025, then retreated by 0.43% to $699000.0 in 2026.
• The last three Non Operating Interest Expenses figures came in at $699000.0 (Q2 2026), $689000.0 (Q1 2026), and $702000.0 (Q4 2025), per Business Quant data.